Ixbi.Si

The company's capital structure is highly leveraged, with a debt-to-equity ratio of 16.17, indicating a significant reliance on debt financing. Its liquidity position is weak, as evidenced by a current ratio of 0.47, suggesting that the company may struggle to meet its short-term obligations. The negative operating cash flow of -3.76 million SGD and free cash flow of -9.49 million SGD further highlight the company's cash flow challenges.

In terms of profitability, IXBI.SI is currently unprofitable, with an operating loss of -10.14 million SGD and a net loss of -10.14 million SGD. The return on equity of -27.78% and return on assets of -0.899% indicate poor capital efficiency and asset utilization. These metrics are significantly below the industry median for pharmaceutical companies, which typically report positive returns and higher gross margins.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to market-specific risks and limits its ability to offset losses in one area with gains in another.

The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. The lack of positive revenue momentum, combined with ongoing losses and negative cash flows, suggests that the company may face challenges in achieving sustainable growth in the near term.

The company's risk profile is elevated, with a medium liquidity risk and a negative net cash position after subtracting total debt. The dilution risk is currently low, but the company's high debt levels and negative cash flows could necessitate future equity or debt financing, which may lead to share dilution.

Recent events, including the company's latest financial filing, indicate ongoing financial stress. The company has not disclosed any material events in the form of earnings calls or press releases that would suggest a turnaround in its financial performance.